Compare GPMT & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPMT | ITRM |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | Ireland |
| Employees | 33 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.0M | 24.3M |
| IPO Year | 2017 | 2018 |
| Metric | GPMT | ITRM |
|---|---|---|
| Price | $2.45 | $0.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $3.13 | ★ $9.00 |
| AVG Volume (30 Days) | 159.2K | ★ 731.7K |
| Earning Date | 11-05-2025 | 02-06-2026 |
| Dividend Yield | ★ 8.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $390,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21.74 | $325.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.61 | $0.36 |
| 52 Week High | $3.23 | $2.10 |
| Indicator | GPMT | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 30.69 | 32.72 |
| Support Level | $2.48 | $0.44 |
| Resistance Level | $2.60 | $0.49 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 13.51 | 0.78 |
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the property.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.